JC
Therapeutic Areas
Novavax Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Nuvaxovid® (NVX-CoV2373) | COVID-19 (primary series & boosters) | Approved/Commercial |
| Covovax™ | COVID-19 | Approved/Commercial |
| COVID-19-Influenza Combination (CIC) Vaccine | COVID-19 and Seasonal Influenza | Phase 3 |
| Quadrivalent Nanoparticle Influenza Vaccine (qNIV) | Seasonal Influenza | Phase 3 |
| Respiratory Syncytial Virus (RSV) Vaccine (ResVax®) | RSV disease in infants via maternal immunization | Phase 3 |
| Malaria Vaccine (R21/Matrix-M) | Malaria | Phase 3 |
| Omicron-Specific COVID-19 Vaccine | COVID-19 (Omicron variants) | Phase 2/3 |
Leadership Team at Novavax
JF
James F. Young
Chief Research and Development Officer
JA
John A. Herrmann III
Executive Vice President, Chief Legal Officer & Corporate Secretary
FD
Filip Dubovsky
Executive Vice President, Chief Medical Officer
JJ
John J. Trizzino
Executive Vice President, Chief Commercial Officer & Chief Business Officer
JM
John M. Kershner
Senior Vice President, Chief Accounting Officer & Treasurer (Interim Principal Financial Officer)
RH
Richard H. Douglas
Chairman of the Board
MA
Michael A. McManus, Jr.
Director
DM
David M. Mott
Director
SC
Stanley C. Erck
Director (Former President & CEO)
GC
Gary C. Evans
Director